Press Release
<< Back
Verastem Receives Orphan Medicinal Product Designation from the European Commission for VS-5584 in Mesothelioma
Verastem’s VS-5584, a dual mTORC1/2 and PI3K inhibitor, is currently being evaluated in a Phase 1 clinical trial in patients with advanced solid tumors and a Phase 1 combination study with VS-6063 in patients with relapsed malignant pleural mesothelioma.
“Following diagnosis, there are very few treatment options for
mesothelioma patients,” said
Under
About Mesothelioma
Mesothelioma is an aggressive form of cancer that occurs in the
mesothelium, the thin layer of tissue that covers the lungs and other
organs. Mesothelioma is associated with exposure to asbestos in most
cases. According to the
About VS-5584
VS-5584 is an orally available compound that has demonstrated potent and
highly selective activity against class 1 PI3K enzymes and dual
inhibitory actions against mTORC1 and mTORC2. In preclinical studies,
VS-5584 has been shown to reduce the percentage of cancer stem cells and
induce tumor regression in chemotherapy-resistant models.
About VS-6063
VS-6063 (defactinib) is an orally available compound designed to target
cancer stem cells through the potent inhibition of focal adhesion kinase
(FAK). Cancer stem cells are an underlying cause of tumor resistance to
chemotherapy, recurrence and ultimate disease progression. Research by
About
Forward-looking statements:
This press release includes forward-looking statements about the
Company’s strategy, future plans and prospects, including statements
regarding the development of the Company’s product candidates, including
VS-5584 and VS-6063, the timeline for clinical development and
regulatory approval of the Company’s product candidates, including the
impact of and any potential benefits from Orphan Medicinal Product
Designation, and the structure of the Company’s pending clinical trials.
The words “anticipate,” “appear,” “believe,” “estimate,” “expect,”
“intend,” “may,” “plan,” “predict,” “project,” “target,” “potential,”
“will,” “would,” “could,” “should,” “continue,” and similar expressions
are intended to identify forward-looking statements, although not all
forward-looking statements contain these identifying words. Each
forward-looking statement is subject to risks and uncertainties that
could cause actual results to differ materially from those expressed or
implied in such statement. Applicable risks and uncertainties include
the risks that the preclinical testing of the Company’s product
candidates and preliminary or interim data from clinical trials may not
be predictive of the results or success of ongoing or later clinical
trials, that data may not be available when we expect it to be, that
enrollment of clinical trials may take longer than expected, that the
Company will be unable to successfully complete the clinical development
of its product candidates, including VS-5584 and VS-6063, that the
development of the Company’s product candidates will take longer or cost
more than planned, and that the Company’s product candidates will not
receive regulatory approval or become commercially successful products.
Other risks and uncertainties include those identified under the heading
“Risk Factors” in the Company’s Annual Report on Form 10-K for the year
ended
Source:
Verastem, Inc.
Brian Sullivan, 781-292-4214
bsullivan@verastem.com